Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...

CEOs have been grilled on tariffs and their impact on business and consumers' wallets in recent earnings calls and interviews ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

According to the nonpartisan Penn Wharton Budget Model, which tracks weekly Treasury data, total spending rose by 6.3%, or $156 billion, since Donald Trump took office, compared to the first four ...

Q1 2025 Earnings Call Transcript April 29, 2025 Pfizer Inc. beats earnings expectations. Reported EPS is $0.92, expectations ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Healthcare stocks have traditionally been seen as a safe haven during market volatility. However, recent developments — particularly President Trump's tariffs and research spending cuts — are changing ...